Product Description
Dexpramipexole is an investigational first-in-class oral tablet that has been shown to lower eosinophils in both blood and tissue. The EXHALE Phase 2 trial was undertaken to examine dexpramipexole efficacy and safety in patients with eosinophilic asthma. (Sourced from: https://www.aaaai.org/tools-for-the-public/latest-research-summaries/the-journal-of-allergy-and-clinical-immunology/2023-the-journal-of-allergy-and-clinical-immunolog/dexpramipexole)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Knopp Biosciences
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Austria, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, France, Georgia, Germany, Hungary, Israel, Italy, Korea, Lithuania, Macedonia, Malaysia, Mexico, Poland, Puerto Rico, Romania, Serbia, South Africa, South Korea, Spain, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 8
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Asthma|Pulmonary Eosinophilia
Phase 2: Chronic Obstructive Pulmonary Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06533553 |
SUSPIRE-1 | P2 |
Active, not recruiting |
Chronic Obstructive Pulmonary Disease |
2025-10-01 |
12% |
2025-05-15 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2023-503693-20-01 |
AR-DEX-22-02 | P3 |
Recruiting |
Asthma |
2026-05-04 |
2025-05-02 |
||
NCT05748600 |
EXHALE-4 | P3 |
Active, not recruiting |
Asthma|Pulmonary Eosinophilia |
2025-09-01 |
39% |
2025-06-14 |
Primary Endpoints |
jRCT2031250129 |
jRCT2031250129 | P3 |
Not yet recruiting |
Asthma |
2028-09-29 |
|||
2024-510810-33-00 |
AR-DEX-22-04 | P3 |
Recruiting |
Asthma |
2027-02-20 |
2025-05-02 |
Treatments |
|
jRCT2031240072 |
jRCT2031240072 | P3 |
Not yet recruiting |
Asthma |
2026-12-11 |
|||
2023-507665-25-00 |
AR-DEX-22-01 | P3 |
Recruiting |
Asthma |
2026-07-27 |
2025-05-02 |
Treatments |
|
2023-509739-22-00 |
AR-DEX-22-03 | P3 |
Active, not recruiting |
Asthma |
2024-09-27 |
2025-05-02 |
Treatments |